Kornimate/medical-research-clean huggingface dataset:
effects of cognitive intervention on cognition, mobility and brain electrocortical activity

Conditions: Cognitive Decline; Cognitive Impairment; Aging; Motor Coordination or Function

Summary: within this project the investigators tested the effectiveness of 2-month of computerized cognitive training (cct) on cognifit online platform on 77 older adults, which were randomly divided into intervention and control group. the investigators tested close (battery of cognitive functions) and far transfer (postural and mobility control, eeg, blood samples) of the cct. additionally, the investigators were interested into seeing a long-lasting effect, therefore participants were brought back to the laboratory 1 year post cct.


Eligibility criteria:
inclusion criteria: * active and healthy older adults with no major health issues * members of the center for daily activity koper (slovenia) * had normal or corrected-to-normal vision; * reported no history of cardiovascular, neurological, or psychiatric conditions exclusion criteria: * younger than 60 * smoking; regular alcohol consumption; * acute or chronic skeletal, neuromuscular, metabolic and cardiovascular disease condition;

Keywords: cognition mobility cognitive reserve eeg/erp
effecti̇vi̇ty of chitosan covered gauze in postpartum hemorrhagic obstetric lacerations

Conditions: Effectiveness of Chitosan Covered Gauze to Stop Bleeding in Post-partum Tears; Comparison of the Effect of Chitosan Covered Gauze With Suturing in Terms of Hemostasis in Post-partum Haemorrhagic Tears

Summary: this study was planned to investigate the efficacy of different treatment methods that can be used in the treatment of hemorrhagic tears that may occur in the postpartum period. the volunteers who will participate in the study will be evaluated during the hospitalization period after delivery and at the end of the puerperium 6 weeks after delivery, in accordance with routine postpartum control examinations. in the treatment of postpartum hemorrhagic tears, the treatment options such as suturing the tears to stop bleeding or applying tampons with bleeding stopping agent (chitosan) and compression effect to the torn area will be determined completely randomly.


Eligibility criteria:
inclusion criteria: patients, 18-48 years old, who gave birth in istanbul trh between march 2025 and march 2027 experiencing 1st and 2nd degree obstetric lacerations with postpartum hemorrhage without the need for anatomical defect repairing and without additional conditions such as uterine atony, placental rest, etc. that may affect the amount of postpartum bleeding. exclusion criteria: patients not fullfilling the inclusion criteria in terms of age limits, time and place of birth or ones who are experiencing 1st and 2nd degree obstetric lacerations with postpartum hemorrhage with the need for anatomical defect repairing and with additional conditions such as uterine atony, placental rest, etc. that may affect the amount of postpartum bleeding.

Keywords: chitosan-covered-gauze post-partum lacerations obstetrical tears
sepsis and hospital mortality

Conditions: Sepsis

Summary: sepsis is one of the leading causes of hospital mortality, with a mortality rate of 20% (world health organization) among vulnerable patients admitted to high-intensity care units such as ccus and inpatient wards. currently, diagnostic criteria such as systemic inflammatory response syndrome (sirs) and the sequential organ failure assessment (sofa) score, although widely used, lack specificity and accuracy. there are no established parameters for early and timely diagnosis. this project aims to address this gap by investigating the variability of blood plasma conductivity and dielectric constant using microwave probes already validated for non-invasive glucose monitoring. the data acquired will be processed using the anritsu vectorstar vna, in order to identify innovative and reliable parameters associated with the presence of severe infections.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * cardiology patients without infection (control group) * patients with sepsis * patients with nosocomial infection * patients with myocarditis, endocarditis, or pericarditis * ability to provide written informed consent exclusion criteria: * patients with severe or chronic medical conditions that may interfere with study results, such as autoimmune diseases, renal or hepatic failure * patients taking medications that could affect the measured biophysical parameters, such as corticosteroids or immunosuppressants * patients with cancer * patients with diseases involving the immune system (e.g., lymphomas, leukemias) * patients with congenital or acquired immunodeficiencies (e.g., hiv) * patients who are unable to read and sign the informed consent form
smartmesh technology in pelvic floor repair procedures

Conditions: Pelvic Organ Prolapse

Summary: pelvic organ prolapse repair involves conservative treatments and surgical treatments. conservative treatments are for patients with moderate prolapse. treatment of symptomatic prolapse remains essentially surgical. according to detailed medical history and a thorough physical exam, surgical techniques may be performed by high abdominal, low vaginal or mixed routes with or without the use of a reinforcing implant. restorelle direct fix is indicated for transvaginal anterior and posterior surgical repair either as mechanical support or as reinforcement of pelvic floor defects. advantages and disadvantages of vaginal prostheses are known but only limited data have been reported on the use of restorelle® in the treatment of pelvic organ prolapse. this study is designed to collect data on the safety and efficacy of restorelle® direct fix in pelvic organ prolapse repair.

between january 2013 and december 2016, in the participating centers, all adult women who underwent surgery to repair pelvic organ prolapse (recurrent or not) through the vagina with the addition of anterior and/or posterior restorelle direct fix prosthesis are eligible. collected data are about the peri-operative period and the data available at the last consultation.

Eligibility criteria:
inclusion criteria: * over 18 * woman who underwent surgery to repair pelvic organ prolapse (recurrent or not) through the vagina with the addition of anterior and/or posterior restorelle direct fix prosthesis * informed and not opposed to the use of her data exclusion criteria: * opposed to the use of her data
vascular response to brachytherapy using functional oct

Conditions: Uveal Melanoma

Summary: the purpose of this study is to learn how blood flows to tumors in patients treated with i-125 plaque brachytherapy for uveal melanoma.

despite having excellent local tumor control rates, uveal melanoma remains a life-threatening cancer, and even eye-sparing therapy with radiation treatment often leads to significant loss of vision. major challenges to providing care to patients with uveal melanoma include the inability to accurately predict long-term vision in an eye treated with radiation, due to a poor understanding of the nature of radiation retinopathy and optic neuropathy. optical coherence tomography (oct) is a commonly used ophthalmic imaging modality that provides precise, real-time data in vivo in a non-invasive manner. our research group has recently developed two novel functional oct technologies: (1) doppler oct to quantitatively measure total retinal flow and (2) oct angiography technology to map optic nerve head, retinal, and choroidal blood flow with unprecedented accuracy. the investigators believe this technology can be utilized to improve understanding of radiation-induced vascular changes in the optic nerve and retina that cause vision loss in patients treated with radiation, as well as provide a tool to monitor tumor response to treatment. in this study, the investigators intend to utilize these novel functional oct technologies to describe the changes over time in optic nerve head and retinal blood flow after i-125 radiation therapy, and to evaluate the relationship between changes in flow and decreased vision. the investigators will also study the association between changes in flow and the total radiation doses received by the optic nerve head and macula, which varies based upon tumor location and size.

Eligibility criteria:
inclusion criteria: * adults age 18 and older with uveal melanomas involving the ciliary body and/or the choroid undergoing i-125 plaque brachytherapy. exclusion criteria: * inability to give informed consent. * inability to maintain stable fixation for oct imaging * significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant * a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control). * blood pressure \> 180/110 (systolic above 180 or diastolic above 110). if blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible. * women who are pregnant or lactating at the time of enrollment due to unknown safety of fluorescein angiography. women that become pregnant during the course of the study may remain enrolled; however, flurorescein and icg angiography will not be performed until they are no longer pregnant or nursing an infant.

Keywords: uveal melanoma brachytherapy radiation ciliary body choroid i-125 plaque brachytherapy
continuing somatostatin analogues upon progression in neuroendocrine tumour patients

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Summary: the sauna trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (gep) neuroendocrine tumours (net) with progressive disease on first-line therapy with somatostatine analogues (ssa). eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (prrt) or targeted therapy, at the discretion of the local investigator). patients within each substudy will be randomised 1:1 between continuation or withdrawal from ssa at the start of second-line systemic therapy. stratification will occur according to study site and according to the ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade 2)).


Eligibility criteria:
inclusion criteria: * age ≥18 years * written informed consent prior to any study-related procedures * eastern cooperative oncology group (ecog) performance status ≤2, * histologically-proven diagnosis of locally advanced or metastatic, non-functional, well-differentiated world health organisation 2019 grade 1-2 gep net * documented radiological disease progression on first-line ssa treatment at label dose or higher * for targeted therapy substudy: indication to start with either sunitinib or everolimus as second-line therapy, according to local investigator * for prrt substudy: indication to start with prrt with lutetium (177lu) oxodotreotide as second-line therapy, according to local investigator exclusion criteria: * indication for chemotherapy treatment of gep net in second-line * presence of poorly differentiated grade 3 neuroendocrine carcinoma (nec), well-differentiated grade 3 net or rapidly progressive net * prior treatment with everolimus, sunitinib or prrt * contra-indication, proven allergy or other indication than functional net for the use of a ssa * patient showing progressive disease while being on a lower than the registered dose * functional net, defined as the presence of clinical and biochemical evidence of a hormonal net-related syndrome * patient undergoing palliative, systemic oncological treatment for other malignancy than gep net * concurrent anti-cancer treatment in another investigational trial * any abnormal findings at screening, clinical finding, including psychiatric and behavioural problems, or any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study * pregnant or lactating patient at screening or if the patient wishes to get pregnant during treatment phase of the trial

Keywords: somatostatin analogues neuroendocrine tumor
a uremic toxin absorbent (ast-120) to treat hospital acquired acute kidney injury

Conditions: Acute Kidney Injury

Summary: hospital acquired acute kidney injury is an important negative outcome predictor for hospitalized patients. uremic toxins accumulated after a given renal insult. some of these uremic toxins are protein bound and may accumulated after renal impairment, owing to both impaired filtration, and inflammation. recent animal studies have reported that accumulation of uremic toxins, namely indoxyl sulfate and p-cresol, would down regulate endothelial progenitor cells and in turn affect renal recovery. elimination of these protein bound uremic toxins with an activated charcoal would help restore endothelial function. we will conduct a double blinded randomized placebo controlled trial, which aims to determine that if oral activated charcoal will retard progression of aki. also, a panel of markers for endothelial function will also be determined.


Eligibility criteria:
this is a prospective randomized placebo controlled trial. all patients admitted to participating centers with newly diagnosed acute kidney injury (aki) will be screened for eligibility. the diagnosis of aki will be determined and staged according to the kigo-aki guideline.11 the inclusion criteria include: 1. age ≥ 20 years old on the day of admission 2. aki develops during admission, as defined with kdigo-aki guideline,11 namely, elevation of serum creatinine above 0.3mg/dl within two days, above 1.5times baseline. patients with the following conditions will be excluded: 1. baseline estimated glomerular filtration rates (egfr) less than 30ml/min/1.73m2 or greater than 90ml/min/1.73m2 according to mdrd equation. 2. acute kidney injury diagnosed in the indexed admission (according to baseline creatinine) 3. ileus or under fasting status 4. previous gastrointestinal operation. 5. chronic constipation, as defined with bowel movement less than three times a day. if usage of oral laxatives can achieve bowel movement of more than 3 times a day, this patient will not be excluded. 6. patients had ever undergone any modality of renal replacement therapy (rrt) 7. patients with major hemorrhage, as defined with requirement of blood transfusion during index admission. 8. patients with a biopsy proved or clinically diagnosed liver cirrhosis, child classification b or c. 9. patients with a congestive heart failure of nyha class iii or iv, or requirement of inotropic agents. 10. patients with a chronic lung disease requiring non-invasive or invasive positive pressure ventilation. 11. solid organ or hematological transplantation donors. 12. patients who had been diagnosed as aki in the index hospitalization, as defined with kdigo 2012 criteria. 13. patients with oliguric acute kidney injury, as defined with less than 500cc/day. 14. evidence of obstructive acute kidney injury under kidney echosonography.

Keywords: acute kidney injury indoxylsulfate p-cresol ast-120
effects of a combined program of pelvic floor muscle training and yoga

Conditions: Genitourinary Symptoms; Sexual Function; Quality of Life

Summary: this study aims to examine the effects of pelvic floor muscle training (pfmt) combined with yoga on relieving genitourinary symptoms, symptom-related quality of life, and improving sexual function in women with breast cancer. this study is a parallel randomized study with two groups. women will be assigned to the experimental or control group by using the block randomization method. the experimental group will receive regular care and a 12-week program of pfmt and yoga. the control group will receive regular care. we collect relevant data from both groups at baseline and 4, 8, 12, and 24 weeks after baseline during the study period.

this study will be conducted with the approval obtained from the institutional review board (irb) of mackay memorial hospital. this parallel-two-group randomized experimental study including an experimental group and a control group examines the effects of pelvic floor muscle training (pfmt) combined with yoga on genitourinary symptoms, symptom-related quality of life, and sexual function. a sample of women with breast cancer experiencing ≥1 genitourinary symptom(s) will be recruited and assigned to an experimental group or a control group by using the block randomization method. the experimental group will receive regular care and a 12-week program of pfmt and yoga. we will provide the experimental group with 12 days of online group practice sections of pfmt and yoga (weekly 60-minute practice incudes yoga 40 minutes, pfmt 15 minutes, and reflection 5 minutes). we expect them to perform 36 days of home-based practice of pfmt and yoga with 3 days/week of yoga for 40 minutes and pfmt for 15 minutes. the control group will receive regular care and relevant educational materials after data collection. information will be collected at five time points: baseline and 4, 8, 12, and 24 weeks after baseline. generalized estimating equation procedures will be used to examine the effects of the intervention. we hypothesized that the experimental group will display more significant improvements in genitourinary symptoms, symptom-related influences, and sexual function than those shown in the control group.

Eligibility criteria:
inclusion criteria: * women aged 20-60 years * women with a confirmed diagnosis of breast cancer (stages i-iii) for ≥3 months * women who experience ≥1 genitourinary symptom(s) exclusion criteria: * women with other types of cancer diagnoses (e.g., endometrial cancer and ovarian cancer) * women with inadequately managed chronic conditions (e.g., an individual with diabetes having hba1c level \>7%)
high-density eeg in neurological disorders

Conditions: Epilepsy; Tumor; Healthy

Summary: the purpose of the study is to use a new method of high-density electroencephalogram (hd-eeg) recording to map brain areas important for movement, sensation, language, emotion, and cognition.

this study will measure brain waves using high-density eeg. participants will be asked wear a cap with electrodes attached to it. during the recording, participants may be asked to rest, sleep, or complete a task. the tasks involve viewing pictures, answering questions, speaking, or moving an arm or leg. recordings generally last between 60-120 minutes.\*

Eligibility criteria:
inclusion criteria: * able to perform the tasks * able to give own consent exclusion criteria: * any neurologic or psychiatric diagnosis such as stroke, tumor, or psychosis judged to interfere with high-density eeg.

Keywords: electroencephalogram (eeg) epilepsy lesion brain language movement sensation mapping dense-array eeg high-density eeg hd-eeg stroke electrical impedance tomography
a safety study of sabin inactivated poliovirus vaccine in infants

Conditions: Poliomyelitis

Summary: the purpose of this study is to evaluate the safety of sabin inactivated poliovirus vaccine (vero cell)(sipv)in the primary immunization of infants at the age of 2 months and booster immunization of children at the age of 18 months, and the simultaneous immunization with other vaccines of children at the age of 2 months and older, so as to provide reference for the improvement of immunization strategy.

this study is an open and observational phase ⅳ clinical trial of sabin inactivated poliovirus vaccine.the purpose of this study is to evaluate the safety of sabin inactivated poliovirus vaccine (vero cell)(sipv)in the primary immunization of infants at the age of 2 months and booster immunization of children at the age of 18 months, and the simultaneous immunization with other vaccines of children at the age of 2 months and older, so as to provide reference for the improvement of immunization strategy.a total of 3200 subjects including 2000 subjects aged 2\~3 months in primary immunization group,1200 subjects aged 18 months in primary immunization group will be enrolled and will receive sipv vaccine or sipv vaccine and other vaccines simultaneously.

Eligibility criteria:
inclusion criteria: * infants aged 2-3 months should be involved in primary immunization and they have not received sabin strain inactivated polio vaccine (vero cell) in the past; * children aged 18 months should be immunized with the first three doses of sabin strain inactivated polio vaccine (vero cell) and they have not received any inactivated or attenuated live vaccines in the past 14 days; * the guardian agrees to sign the informed consent and voluntarily use the mobile app to participate in the follow-up visits. exclusion criteria: * allergic to the active ingredient in the vaccine, any inactive ingredient, or substance used in the manufacturing process; * allergic to this product or similar vaccines in the past; * patients with severe chronic diseases or allergies; * patients with fever or acute illness. the exclusion criteria for the second and third doses: * any serious adverse events that are causally related to vaccination; * severe anaphylaxis or hypersensitivity after vaccination (including hives and rashes within 30 minutes of vaccination); * any confirmed or suspected autoimmune or immunodeficiency disease, including human immunodeficiency virus (hiv) infection; * acute or newly emerging chronic diseases occur at the time of vaccination; * other reactions (including severe pain, severe swelling, severe limitation of movement, persistent high fever, severe headache, or other systemic or local reactions), as determined by the investigator; * having an acute illness at the time of vaccination (acute illness is defined as moderate or severe illness with or without fever); * axillary temperature \>37℃ during vaccination.